Tralokinumab for Dupilumab Failures

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2025-04-01

Summary

24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.

• Phase: PHASE4

Details

• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey
• Collaborator: LEO Pharma
• Treatments: tralokinumab